News & Insights

Unified National Lab-Test Pricing Is Coming! An End to "Same Item, Different Prices" — What It Means for Patients, Hospitals and the IVD Industry

In 2025, the healthcare sector saw a major new policy move: the guidelines for establishing pricing items for laboratory and pathology medical services have been drafted and have entered the public-comment stage, with official release expected within the year. This means laboratory-test pricing in China will finally leave behind the fragmented era of "province-by-province pricing with wide disparities" and enter a new phase of unified national standards. Patients seeking care across regions, hospitals adjusting their operating strategies and companies working in in vitro diagnostics (IVD) will all face a deep transformation involving cost, efficiency and service quality.

IVD Half-Year Reports in Focus: Test-Package Unbundling Is the Biggest Challenge as Industry Consolidation Accelerates

The "report cards" of the in vitro diagnostics (IVD) industry for the first half of 2025 are out. Judging from the interim reports disclosed so far, the whole industry is under unprecedented pressure, and falling revenue and profit have become the norm for most companies. Among the many factors at work, the impact of the "test-package unbundling" policy far exceeds that of centralized procurement, and it is profoundly reshaping the industry landscape.

Healthcare Security Authority: Prices of 76 More Lab Test Items to Be Cut

On August 11, the Zhejiang Provincial Healthcare Security Administration issued the Notice of the Zhejiang Provincial Healthcare Security Administration on Publishing the First Round of Dynamic Price Adjustments under the Pilot Program for Deepening Medical Service Price Reform (Draft for Comments).

GP73 Chemiluminescence Kit Developed by Peking University Team Gains Medical Device Registration

Guangdong's medical products administration has approved Class II registration for a Golgi protein 73 (GP73) assay kit (chemiluminescence immunoassay), offering a new tool for the non-invasive diagnosis of liver fibrosis and cirrhosis.

Source: 临床肝胆病杂志（转载自搜狐号）

2025 Laboratory Medicine & In Vitro Diagnostics Expo Opens in Hangzhou with More Than 1,300 Exhibitors

The world's largest in vitro diagnostics expo comes to Hangzhou, bringing together more than 1,300 exhibitors from 23 countries and regions and over 100,000 professional visitors.

Source: 网易新闻

IVD Industry Under Pressure in 2024 Earnings: More Than 70% of Companies Posted Losses

As of early 2025, only 8 of the 32 IVD companies that published 2024 earnings forecasts were profitable; 24 reported losses totaling over RMB 5.6 billion, as the industry endures a painful adjustment.

Source: 21世纪经济报道（新浪财经转载）

2025 IVD Volume-Based Procurement Outlook: Centralized Procurement Deepens as the Industry Accelerates Change

Volume-based procurement of IVD reagents continues to advance in 2025: Anhui leads centralized procurement of cardiac marker reagents, Gansu leads procurement of routine laboratory reagents, and Jiangsu includes genetic testing services in centralized procurement for the first time.

Source: 小桔灯网（转载自微博）

2024 IVD Industry Trends Analysis

An in-depth analysis of the latest trends in the in vitro diagnostics (IVD) industry in 2024, covering technological innovation, market dynamics and future opportunities.

A Guide to Routine Maintenance and Reagent Selection for Hematology Analyzers

A detailed guide to the key points of routine maintenance for hematology analyzers and how to choose suitable compatible reagents to ensure accurate test results.

Chemiluminescence Immunoassay Reagent Selection and Quality Control

A professional analysis of the key points in chemiluminescence immunoassay reagent selection and of quality control measures, helping laboratories improve testing quality.

Biochemistry Analyzer Market Trends and Reagent Opportunities

An analysis of global biochemistry analyzer market trends, exploring the opportunities and challenges for domestic reagents.